Press Releases Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:52 2024-05-01 am EDT			5-day change	1st Jan Change
28.9 ^DKK	-1.87%		+4.25%	-16.33%

Apr. 09	H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	MT
Apr. 09	Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	Apr. 09	AQ
Lundbeck : Articles of Association	Apr. 02	PU
Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia	Mar. 27	AQ
Lundbeck held its Annual General Meeting on 20 March 2024 at the company's registered office	Mar. 20	AQ
Lundbeck's potential first-in-class therapy for migraine prevention enters advanced clinical stage	Mar. 15	AQ
Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders	Mar. 05	AQ
Notice of Annual General Meeting	Feb. 23	AQ
Lundbeck announces changes to Executive Management	Feb. 23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer